Brian R. Curtis
Research Subjects
Research Interests
Brian R. Curtis has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Mia J. Sullivan
Platelet & Neutrophil Immunology Lab
7 shared publicationsRichard H. Aster
Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, Wisconsin
6 shared publications- Richard C. Aster
Department of Geosciences and Warner College of Natural Resources Colorado State University Fort Collins CO USA
4 shared publications Janice G. McFarland
Platelet & Neutrophil Immunology Lab, Bloodcenter of Wisconsin, Milwaukee, Wisconsin
3 shared publicationsJulie Peterson
Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, Wisconsin
2 shared publicationsAllison Ujcich
Platelet and Neutrophil Immunology Laboratory, Milwaukee, Wisconsin
1 shared publication
Latest Publications
- 8 December 2017
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2017 (1) , 187-193
Non–chemotherapy drug–induced neutropenia: key points to manage the challenges
Non–chemotherapy idiosyncratic drug–induced neutropenia (IDIN) is a relatively rare but potentially fatal disorder that occurs in susceptible individuals, with an incidence of 2.4 to 15.4 cases per million population. Affected patients typically experience severe neutropenia within several weeks to several months after first exposure to a drug, and mortality is ∼5%. The drugs most frequently associated with IDIN include metamizole, clozapine, sulfasalazine, thiamazole, carbimazole, amoxicillin, cotrimoxazole, ticlopidine, and valganciclovir. The idiosyncratic nature of IDIN, the lack of mouse models and diagnostic testing, and its low overall incidence make rigorous studies to elucidate possible mechanisms exceptionally difficult. An immune mechanism for IDIN involving neutrophil destruction by hapten (drug)-specific antibodies and drug-induced autoantibodies is frequently suggested, but strong supporting evidence is lacking. Although laboratory testing for neutrophil drug-dependent antibodies is rarely performed because of the complexity and low sensitivity of tests currently in use, these assays could possibly be enhanced by using reactive drug metabolites in place of the parent drug. Patients typically experience acute, severe neutropenia, or agranulocytosis (<0.5 × 109 neutrophils/L) and symptoms of fever, chills, sore throat, and muscle and joint pain. Diagnosis can be difficult, but timely recognition is critical because if left untreated, there is an increase in mortality. Expanded studies of the production and mechanistic role of reactive drug metabolites, genetic associations, and improved animal models of IDIN are essential to further our understanding of this important disorder.
- 8 December 2017
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2017 (1) , 187-193
Non–chemotherapy drug–induced neutropenia: key points to manage the challenges
Non–chemotherapy idiosyncratic drug–induced neutropenia (IDIN) is a relatively rare but potentially fatal disorder that occurs in susceptible individuals, with an incidence of 2.4 to 15.4 cases per million population. Affected patients typically experience severe neutropenia within several weeks to several months after first exposure to a drug, and mortality is ∼5%. The drugs most frequently associated with IDIN include metamizole, clozapine, sulfasalazine, thiamazole, carbimazole, amoxicillin, cotrimoxazole, ticlopidine, and valganciclovir. The idiosyncratic nature of IDIN, the lack of mouse models and diagnostic testing, and its low overall incidence make rigorous studies to elucidate possible mechanisms exceptionally difficult. An immune mechanism for IDIN involving neutrophil destruction by hapten (drug)-specific antibodies and drug-induced autoantibodies is frequently suggested, but strong supporting evidence is lacking. Although laboratory testing for neutrophil drug-dependent antibodies is rarely performed because of the complexity and low sensitivity of tests currently in use, these assays could possibly be enhanced by using reactive drug metabolites in place of the parent drug. Patients typically experience acute, severe neutropenia, or agranulocytosis (<0.5 × 109 neutrophils/L) and symptoms of fever, chills, sore throat, and muscle and joint pain. Diagnosis can be difficult, but timely recognition is critical because if left untreated, there is an increase in mortality. Expanded studies of the production and mechanistic role of reactive drug metabolites, genetic associations, and improved animal models of IDIN are essential to further our understanding of this important disorder.
- 18 May 2017
- Published by Wiley in Transfusion
- Vol. 57 (7) , 1847-1848
Severe neonatal alloimmune thrombocytopenia caused by maternal sensitization against a new low-frequency alloantigen (Domb ) located on platelet glycoprotein IIIa
- 18 May 2017
- Published by Wiley in Transfusion
- Vol. 57 (7) , 1847-1848
Severe neonatal alloimmune thrombocytopenia caused by maternal sensitization against a new low-frequency alloantigen (Domb ) located on platelet glycoprotein IIIa
- 25 April 2017
- Published by Wiley in Transfusion
- Vol. 57 (7) , 1724-1733
Detection and identification of platelet antibodies using a sensitive multiplex assay system–platelet antibody bead array
BACKGROUND: Tests for platelet‐specific antibodies are important in the diagnosis of immune platelet disorders. Monoclonal antibody glycoprotein capture assays have been the gold standards in platelet antibody detection for almost 30 years. However, such assays are complex and cumbersome to perform, which limits their routine use. We report the performance of a newly developed, easy to perform platelet antibody bead array (PABA) for the detection of platelet‐specific antibodies.STUDY DESIGN AND METHODS: PABA is the equivalent of the monoclonal antigen capture enzyme‐linked immunosorbent assay (ELISA) (MACE) on a bead and instead with fluorescent detection of immunoglobulin (Ig)G platelet antibodies by Luminex. Antibodies against platelet glycoproteins (GP) GPIIb/IIIa, GPIb/IX, GPIa/IIa, GPIV, and class I human leukocyte antigen (HLA) could be detected in a patient's serum simultaneously in a single well of a microplate. Results from 80 patient samples and 20 normal donor samples were compared using PABA, MACE, and a commercial ELISA kit.RESULTS: PABA detected all antibodies, with specificity for human platelet antigens (HPAs) HPA‐1a, HPA‐1b, HPA‐2a, HPA‐2b, HPA‐3a, HPA‐3b, HPA‐4a, HPA‐4b, HPA‐5a, HPA‐5b, HPA‐15b, and HLA. Overall, compared with MACE, the sensitivity and specificity of PABA were 99% and 97%, respectively, and both were significantly better than those of the commercial ELISA. PABA had greater analytic sensitivity than MACE for HPA‐1a, HPA‐3a, and HPA‐5b antibodies. In addition, PABA detected HPA‐5b and HPA‐3b antibodies that were missed by MACE. The overall false‐positive rate of PABA compared with MACE was 2.7%.CONCLUSIONS: The PABA is a rapid, highly sensitive and specific, multiplex bead‐based assay for detecting human platelet antibodies. Such a simple yet high‐throughput platform will facilitate practical, routine testing for the identification of platelet‐specific antibodies.
- 25 April 2017
- Published by Wiley in Transfusion
- Vol. 57 (7) , 1724-1733
Detection and identification of platelet antibodies using a sensitive multiplex assay system–platelet antibody bead array
BACKGROUND: Tests for platelet‐specific antibodies are important in the diagnosis of immune platelet disorders. Monoclonal antibody glycoprotein capture assays have been the gold standards in platelet antibody detection for almost 30 years. However, such assays are complex and cumbersome to perform, which limits their routine use. We report the performance of a newly developed, easy to perform platelet antibody bead array (PABA) for the detection of platelet‐specific antibodies.STUDY DESIGN AND METHODS: PABA is the equivalent of the monoclonal antigen capture enzyme‐linked immunosorbent assay (ELISA) (MACE) on a bead and instead with fluorescent detection of immunoglobulin (Ig)G platelet antibodies by Luminex. Antibodies against platelet glycoproteins (GP) GPIIb/IIIa, GPIb/IX, GPIa/IIa, GPIV, and class I human leukocyte antigen (HLA) could be detected in a patient's serum simultaneously in a single well of a microplate. Results from 80 patient samples and 20 normal donor samples were compared using PABA, MACE, and a commercial ELISA kit.RESULTS: PABA detected all antibodies, with specificity for human platelet antigens (HPAs) HPA‐1a, HPA‐1b, HPA‐2a, HPA‐2b, HPA‐3a, HPA‐3b, HPA‐4a, HPA‐4b, HPA‐5a, HPA‐5b, HPA‐15b, and HLA. Overall, compared with MACE, the sensitivity and specificity of PABA were 99% and 97%, respectively, and both were significantly better than those of the commercial ELISA. PABA had greater analytic sensitivity than MACE for HPA‐1a, HPA‐3a, and HPA‐5b antibodies. In addition, PABA detected HPA‐5b and HPA‐3b antibodies that were missed by MACE. The overall false‐positive rate of PABA compared with MACE was 2.7%.CONCLUSIONS: The PABA is a rapid, highly sensitive and specific, multiplex bead‐based assay for detecting human platelet antibodies. Such a simple yet high‐throughput platform will facilitate practical, routine testing for the identification of platelet‐specific antibodies.
- 7 September 2015
- Published by Wiley in British Journal of Haematology
- Vol. 171 (5) , 671-682
Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) occurs in c. 1 in 1000 births and is caused by maternal antibodies against human platelet alloantigens that bind incompatible fetal platelets and promote their clearance from the circulation. Affected infants can experience bleeding, bruising and, in severe cases, intracranial haemorrhage and even death. As maternal screening is not routinely performed, and first pregnancies can be affected, most cases are diagnosed at delivery of a first affected pregnancy. Unlike its erythrocyte counterpart, Haemolytic Disease of the Fetus and Newborn, there is no prophylactic treatment for FNAIT. This report will review recent advances made in understanding the pathogenesis of FNAIT: the platelet alloantigens involved, maternal exposure and sensitization to fetal platelet antigens, properties of platelet Immunoglobulin G antibodies, maternal-fetal antibody transport mechanisms and efforts to develop an effective FNAIT prophylaxis.
- 7 September 2015
- Published by Wiley in British Journal of Haematology
- Vol. 171 (5) , 671-682
Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) occurs in c. 1 in 1000 births and is caused by maternal antibodies against human platelet alloantigens that bind incompatible fetal platelets and promote their clearance from the circulation. Affected infants can experience bleeding, bruising and, in severe cases, intracranial haemorrhage and even death. As maternal screening is not routinely performed, and first pregnancies can be affected, most cases are diagnosed at delivery of a first affected pregnancy. Unlike its erythrocyte counterpart, Haemolytic Disease of the Fetus and Newborn, there is no prophylactic treatment for FNAIT. This report will review recent advances made in understanding the pathogenesis of FNAIT: the platelet alloantigens involved, maternal exposure and sensitization to fetal platelet antigens, properties of platelet Immunoglobulin G antibodies, maternal-fetal antibody transport mechanisms and efforts to develop an effective FNAIT prophylaxis.
- 1 September 2015
- Published by Wiley in Transfusion
- Vol. 56 (1) , 101-106
Two cases of maternal alloimmunization against human neutrophil alloantigen‐4b, one causing severe alloimmune neonatal neutropenia
BACKGROUND: Human neutrophil antigen (HNA)−4a/4bw is encoded by 230G>A in ITGAM, which results in an Arg61His substitution of the αM chain (CD11b) of complement receptor 3 (CR3; CD11b/18 or Mac‐1). HNA‐4a antibodies have been detected in the sera of female blood donors and in maternal sera that caused alloimmune neonatal neutropenia (ANN), in which maternal immunoglobulin (Ig)G antibodies against a paternally inherited HNA cross the placenta and destroy fetal and neonatal neutrophils. However, to date, antibodies specific for HNA‐4b have not been reported. Here, we report the first two examples of HNA‐4b antibodies.STUDY DESIGN AND METHODS: The two sera studied were both from previously pregnant females, one a multiparous female blood donor implicated in two separate transfusion reactions and the second a mother whose first pregnancy resulted in the birth of a severely neutropenic (0 × 106 neutrophils/L) infant affected with ANN. Serum neutrophil antibody testing was by flow cytometry and CD11b/18 monoclonal antibody immobilization of granulocyte antigens assay, and HNA genotyping was performed by polymerase chain reaction with sequence‐specific priming and allele‐specific 5′ exonuclease assays.RESULTS: Sera from both women contained IgG antibodies reactive only with HNA‐4b+ neutrophils and both typed HNA‐4a/a. Both were immunized through pregnancy since their husbands and children all typed HNA‐4a/b.CONCLUSIONS: The serologic results, together with the genotype results, confirm that these are the first reported cases of neutrophil antibodies specific for HNA‐4b.
- 1 September 2015
- Published by Wiley in Transfusion
- Vol. 56 (1) , 101-106
Two cases of maternal alloimmunization against human neutrophil alloantigen‐4b, one causing severe alloimmune neonatal neutropenia
BACKGROUND: Human neutrophil antigen (HNA)−4a/4bw is encoded by 230G>A in ITGAM, which results in an Arg61His substitution of the αM chain (CD11b) of complement receptor 3 (CR3; CD11b/18 or Mac‐1). HNA‐4a antibodies have been detected in the sera of female blood donors and in maternal sera that caused alloimmune neonatal neutropenia (ANN), in which maternal immunoglobulin (Ig)G antibodies against a paternally inherited HNA cross the placenta and destroy fetal and neonatal neutrophils. However, to date, antibodies specific for HNA‐4b have not been reported. Here, we report the first two examples of HNA‐4b antibodies.STUDY DESIGN AND METHODS: The two sera studied were both from previously pregnant females, one a multiparous female blood donor implicated in two separate transfusion reactions and the second a mother whose first pregnancy resulted in the birth of a severely neutropenic (0 × 106 neutrophils/L) infant affected with ANN. Serum neutrophil antibody testing was by flow cytometry and CD11b/18 monoclonal antibody immobilization of granulocyte antigens assay, and HNA genotyping was performed by polymerase chain reaction with sequence‐specific priming and allele‐specific 5′ exonuclease assays.RESULTS: Sera from both women contained IgG antibodies reactive only with HNA‐4b+ neutrophils and both typed HNA‐4a/a. Both were immunized through pregnancy since their husbands and children all typed HNA‐4a/b.CONCLUSIONS: The serologic results, together with the genotype results, confirm that these are the first reported cases of neutrophil antibodies specific for HNA‐4b.
- 15 December 2014
- Published by Wiley in Transfusion
- Vol. 55 (6pt2) , 1584-1585
A new low-frequency alloantigen (Khab) located on platelet glycoprotein IIIa as a cause of maternal sensitization leading to neonatal alloimmune thrombocytopenia
- 15 December 2014
- Published by Wiley in Transfusion
- Vol. 55 (6pt2) , 1584-1585
A new low-frequency alloantigen (Khab) located on platelet glycoprotein IIIa as a cause of maternal sensitization leading to neonatal alloimmune thrombocytopenia
- 16 September 2013
- Published by Wiley in Vox Sanguinis
- Vol. 106 (2) , 93-102
Human platelet antigens – 2013
To date, 33 human platelet alloantigens (HPAs) have been identified on six functionally important platelet glycoprotein (GP) complexes and have been implicated in alloimmune platelet disorders including foetal and neonatal alloimmune thrombocytopenia (FNAIT), posttransfusion purpura (PTP) and multitransfusion platelet refractoriness (MPR). The greatest number of recognized HPA (20 of 33) resides on the GPIIb/IIIa complex, which serves as the receptor for ligands important in mediating haemostasis and inflammation. These include HPA‐1a, the most commonly implicated HPA in FNAIT and PTP in Caucasian populations. Other platelet GP complexes, GPIb/V/IX, GPIa/IIa and CD109, express the remaining 13 HPAs. Of the recognized HPAs, 12 occur as six serologically and genetically defined biallelic ‘systems’ where the –a form designates the higher frequency allele and the –b form, the lower. Twenty‐one other HPAs are low‐frequency or rare antigens for which postulated higher frequency –a alleles have not yet been identified as antibody specificities. In addition to the HPA markers, platelets also express ABO and human leucocyte antigen (HLA) antigens; antibodies directed at the former are occasionally important in FNAIT, and to the latter, in MPR.
- 16 September 2013
- Published by Wiley in Vox Sanguinis
- Vol. 106 (2) , 93-102
Human platelet antigens – 2013
To date, 33 human platelet alloantigens (HPAs) have been identified on six functionally important platelet glycoprotein (GP) complexes and have been implicated in alloimmune platelet disorders including foetal and neonatal alloimmune thrombocytopenia (FNAIT), posttransfusion purpura (PTP) and multitransfusion platelet refractoriness (MPR). The greatest number of recognized HPA (20 of 33) resides on the GPIIb/IIIa complex, which serves as the receptor for ligands important in mediating haemostasis and inflammation. These include HPA‐1a, the most commonly implicated HPA in FNAIT and PTP in Caucasian populations. Other platelet GP complexes, GPIb/V/IX, GPIa/IIa and CD109, express the remaining 13 HPAs. Of the recognized HPAs, 12 occur as six serologically and genetically defined biallelic ‘systems’ where the –a form designates the higher frequency allele and the –b form, the lower. Twenty‐one other HPAs are low‐frequency or rare antigens for which postulated higher frequency –a alleles have not yet been identified as antibody specificities. In addition to the HPA markers, platelets also express ABO and human leucocyte antigen (HLA) antigens; antibodies directed at the former are occasionally important in FNAIT, and to the latter, in MPR.
- 5 February 2013
- Published by Wiley in Transfusion
- Vol. 53 (10) , 2158-2163
Protamine‐induced immune thrombocytopenia
Background: Protamine is widely used to reverse the anticoagulant effects of heparin. Although mild thrombocytopenia is common in patients given protamine after cardiac procedures, acute severe thrombocytopenia has not been described. We encountered a patient who experienced profound thrombocytopenia and bleeding shortly after administration of protamine and performed studies to characterize the responsible mechanism.Study Design and Methods: Patient serum was studied for antibodies that recognize protamine, heparin‐protamine complexes, and platelets (PLTs) treated with protamine using flow cytometry, enzyme‐linked immunosorbent assay, and serotonin release from labeled PLTs.Results: A high‐titer immunoglobulin G antibody was detected in patient serum that recognizes protamine in a complex with heparin or PLT surface glycosaminoglycans (GAGs) and activates PLTs treated with protamine at concentrations achieved in vivo after protamine infusion. The antibody is distinctly different from those found in patients with heparin‐induced thrombocytopenia on the basis of its failure to recognize heparin in a complex with PLT factor 4 (PF4) and to release serotonin from labeled PLTs in the absence of protamine.Conclusions: Findings made suggest that the patient's antibody is specific for conformational changes induced in protamine when it reacts with heparin or a PLT surface GAG. Development of severe thrombocytopenia after treatment of this patient with protamine defines a previously undescribed mechanism of drug‐induced immune thrombocytopenia. Patients given protamine who produce this type of antibody may be at risk of experiencing thrombocytopenia if given the drug a second time while antibody is still present.
- 5 February 2013
- Published by Wiley in Transfusion
- Vol. 53 (10) , 2158-2163
Protamine‐induced immune thrombocytopenia
Background: Protamine is widely used to reverse the anticoagulant effects of heparin. Although mild thrombocytopenia is common in patients given protamine after cardiac procedures, acute severe thrombocytopenia has not been described. We encountered a patient who experienced profound thrombocytopenia and bleeding shortly after administration of protamine and performed studies to characterize the responsible mechanism.Study Design and Methods: Patient serum was studied for antibodies that recognize protamine, heparin‐protamine complexes, and platelets (PLTs) treated with protamine using flow cytometry, enzyme‐linked immunosorbent assay, and serotonin release from labeled PLTs.Results: A high‐titer immunoglobulin G antibody was detected in patient serum that recognizes protamine in a complex with heparin or PLT surface glycosaminoglycans (GAGs) and activates PLTs treated with protamine at concentrations achieved in vivo after protamine infusion. The antibody is distinctly different from those found in patients with heparin‐induced thrombocytopenia on the basis of its failure to recognize heparin in a complex with PLT factor 4 (PF4) and to release serotonin from labeled PLTs in the absence of protamine.Conclusions: Findings made suggest that the patient's antibody is specific for conformational changes induced in protamine when it reacts with heparin or a PLT surface GAG. Development of severe thrombocytopenia after treatment of this patient with protamine defines a previously undescribed mechanism of drug‐induced immune thrombocytopenia. Patients given protamine who produce this type of antibody may be at risk of experiencing thrombocytopenia if given the drug a second time while antibody is still present.
- 1 May 2012
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 18 (22) , 3285-3292
Future Preventive and Therapeutic Targets for Transfusion-Related Acute Lung Injury
Abstract: Transfusion-related acute lung injury (TRALI) has been the leading cause of transfusion-associated death for nearly a decade. Recent TRALI mitigation strategies focused on reduction of leukocyte antibodies in high volume plasma products appear to be successful in reducing TRALI events and deaths, but additional preventive measures are needed. Future possibilities include, screening of donors for neutrophil antibodies, processing of blood products to reduce or remove biologic response modifiers, and the more judicious use of blood. There are currently no specific TRALI therapies. The pathogenesis of TRALI and acute lung injury-acute respiratory distress syndrome (ALI-ARDS) is quite similar; both involving interactions of activated platelets, neutrophils, and pulmonary endothelium resulting in lung damage, capillary leak, and pulmonary edema. Greater understanding of these interactions and the key molecules involved will lead to development of potential new targets for therapy. In this review, future possible preventive measures to further reduce the occurrence of TRALI will be discussed, including TRALI caused by biologic response modifiers (BRMs), like bioactive lipids and sCD40L, which are not addressed by current preventive actions that only target leukocyte antibodies in high-volume plasma products. Insights already gained from studies of ALI-ARDS treatments will be summarized and discussed as possible therapeutic targets for treatment of patients experiencing TRALI.
- 1 May 2012
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 18 (22) , 3285-3292
Future Preventive and Therapeutic Targets for Transfusion-Related Acute Lung Injury
Abstract: Transfusion-related acute lung injury (TRALI) has been the leading cause of transfusion-associated death for nearly a decade. Recent TRALI mitigation strategies focused on reduction of leukocyte antibodies in high volume plasma products appear to be successful in reducing TRALI events and deaths, but additional preventive measures are needed. Future possibilities include, screening of donors for neutrophil antibodies, processing of blood products to reduce or remove biologic response modifiers, and the more judicious use of blood. There are currently no specific TRALI therapies. The pathogenesis of TRALI and acute lung injury-acute respiratory distress syndrome (ALI-ARDS) is quite similar; both involving interactions of activated platelets, neutrophils, and pulmonary endothelium resulting in lung damage, capillary leak, and pulmonary edema. Greater understanding of these interactions and the key molecules involved will lead to development of potential new targets for therapy. In this review, future possible preventive measures to further reduce the occurrence of TRALI will be discussed, including TRALI caused by biologic response modifiers (BRMs), like bioactive lipids and sCD40L, which are not addressed by current preventive actions that only target leukocyte antibodies in high-volume plasma products. Insights already gained from studies of ALI-ARDS treatments will be summarized and discussed as possible therapeutic targets for treatment of patients experiencing TRALI.
- 13 March 2012
- Published by Wiley in Transfusion
- Vol. 52 (11) , 2368-2374
Determination of neutrophil antigen HNA‐3a and HNA‐3b genotype frequencies in six racial groups by high‐throughput 5′ exonuclease assay
BACKGROUND: People with the human neutrophil antigen (HNA)‐3b/3b type can make HNA‐3a antibodies, which have been reported to cause immune neutropenia disorders and are especially prone to cause severe cases of transfusion‐related acute lung injury. However, knowledge of HNA‐3 allele frequencies outside Caucasian populations is limited. We developed a high‐throughput genotyping assay and determined the HNA‐3a/3b genotype frequencies in six different racial and ethnic groups.STUDY DESIGN AND METHODS: Genotyping utilized TaqMan 5′ exonuclease chemistry and real‐time polymerase chain reaction. A total of 742 DNA samples from six different racial and ethnic groups were genotyped for HNA‐3a and HNA‐3b.RESULTS: The genotyping assay showed 100% sensitivity and specificity compared to sequencing and phenotyping and had high throughput. A significant percentage of Caucasians (6.5%), Han Chinese (16%), and Asian Indians (6%) typed HNA‐3b/3b, but only a small percentage of Hispanics (1%) and no African or Native Americans.CONCLUSIONS: The HNA‐3 genotyping assay had high sensitivity, specificity, and sample throughput. HNA‐3b/b genotype results determined for 742 individuals representing six different racial and ethnic groups showed that there could be a significant risk of producing anti‐HNA‐3a in Chinese, as well as in Caucasian and Asian Indian blood donor populations, but a very low risk in Hispanic, African, or Native American populations.
- 13 March 2012
- Published by Wiley in Transfusion
- Vol. 52 (11) , 2368-2374
Determination of neutrophil antigen HNA‐3a and HNA‐3b genotype frequencies in six racial groups by high‐throughput 5′ exonuclease assay
BACKGROUND: People with the human neutrophil antigen (HNA)‐3b/3b type can make HNA‐3a antibodies, which have been reported to cause immune neutropenia disorders and are especially prone to cause severe cases of transfusion‐related acute lung injury. However, knowledge of HNA‐3 allele frequencies outside Caucasian populations is limited. We developed a high‐throughput genotyping assay and determined the HNA‐3a/3b genotype frequencies in six different racial and ethnic groups.STUDY DESIGN AND METHODS: Genotyping utilized TaqMan 5′ exonuclease chemistry and real‐time polymerase chain reaction. A total of 742 DNA samples from six different racial and ethnic groups were genotyped for HNA‐3a and HNA‐3b.RESULTS: The genotyping assay showed 100% sensitivity and specificity compared to sequencing and phenotyping and had high throughput. A significant percentage of Caucasians (6.5%), Han Chinese (16%), and Asian Indians (6%) typed HNA‐3b/3b, but only a small percentage of Hispanics (1%) and no African or Native Americans.CONCLUSIONS: The HNA‐3 genotyping assay had high sensitivity, specificity, and sample throughput. HNA‐3b/b genotype results determined for 742 individuals representing six different racial and ethnic groups showed that there could be a significant risk of producing anti‐HNA‐3a in Chinese, as well as in Caucasian and Asian Indian blood donor populations, but a very low risk in Hispanic, African, or Native American populations.